ES2553584T3 - Polimorfos de Febuxostat - Google Patents

Polimorfos de Febuxostat Download PDF

Info

Publication number
ES2553584T3
ES2553584T3 ES10167344.0T ES10167344T ES2553584T3 ES 2553584 T3 ES2553584 T3 ES 2553584T3 ES 10167344 T ES10167344 T ES 10167344T ES 2553584 T3 ES2553584 T3 ES 2553584T3
Authority
ES
Spain
Prior art keywords
febuxostat
crystalline form
pharmaceutical composition
crystalline
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10167344.0T
Other languages
English (en)
Spanish (es)
Inventor
Ulrich Griesser
Verena Adamer
Andreas Hotter
Christoph Langes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2553584(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of ES2553584T3 publication Critical patent/ES2553584T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ES10167344.0T 2010-06-25 2010-06-25 Polimorfos de Febuxostat Active ES2553584T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10167344.0A EP2399911B1 (en) 2010-06-25 2010-06-25 Polymorphs of Febuxostat

Publications (1)

Publication Number Publication Date
ES2553584T3 true ES2553584T3 (es) 2015-12-10

Family

ID=43033242

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10167344.0T Active ES2553584T3 (es) 2010-06-25 2010-06-25 Polimorfos de Febuxostat
ES11727454.8T Active ES2553574T3 (es) 2010-06-25 2011-06-24 Polimorfos de un principio activo farmacéutico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11727454.8T Active ES2553574T3 (es) 2010-06-25 2011-06-24 Polimorfos de un principio activo farmacéutico

Country Status (7)

Country Link
US (1) US8946441B2 (pl)
EP (3) EP2399911B1 (pl)
CA (1) CA2802937C (pl)
DK (2) DK2399911T3 (pl)
ES (2) ES2553584T3 (pl)
PL (2) PL2399911T3 (pl)
WO (1) WO2011161245A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2399911T3 (en) * 2010-06-25 2015-09-07 Sandoz Ag Polymorphs of Febuxostat.
CN103396378B (zh) * 2013-07-29 2015-06-10 杭州朱养心药业有限公司 非布司他结晶
CZ27857U1 (cs) 2014-12-12 2015-02-23 Zentiva, K.S. Formulace obsahující tuhý roztok febuxostatu

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1275126A (zh) 1998-06-19 2000-11-29 帝人株式会社 2－(3－氰基－4－异丁氧基苯基)－4－甲基－5－噻唑甲酸的多晶型体及其制备方法
SI1488790T1 (sl) 2002-03-28 2014-09-30 Teijin Pharma Limited Trden pripravek, ki vsebuje eno samo kristalno a-obliko derivata tiazolkarboksilne kisline
KR101310002B1 (ko) 2009-06-10 2013-09-25 테바 파마슈티컬 인더스트리즈 리미티드 페북소스타트의 결정형
CN101648926B (zh) * 2009-07-09 2011-11-16 石药集团欧意药业有限公司 一种非布司他晶型及其制备方法
CN101817801A (zh) 2009-08-12 2010-09-01 北京红惠新医药科技有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸新晶型k及其他晶型的制备方法
DK2399911T3 (en) 2010-06-25 2015-09-07 Sandoz Ag Polymorphs of Febuxostat.

Also Published As

Publication number Publication date
EP2977372A1 (en) 2016-01-27
CA2802937A1 (en) 2011-12-29
DK2399911T3 (en) 2015-09-07
EP2399911A1 (en) 2011-12-28
US20130137734A1 (en) 2013-05-30
PL2585445T3 (pl) 2016-01-29
WO2011161245A3 (en) 2012-03-08
EP2977372B1 (en) 2019-05-08
ES2553574T3 (es) 2015-12-10
EP2585445A2 (en) 2013-05-01
PL2399911T3 (pl) 2016-01-29
US8946441B2 (en) 2015-02-03
CA2802937C (en) 2020-02-25
EP2585445B1 (en) 2015-08-19
DK2585445T3 (en) 2015-09-07
WO2011161245A2 (en) 2011-12-29
EP2399911B1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
ES2805534T3 (es) Polimorfos de 20,23-piperidinil-5-O-micaminosiltilonolida
CN104797566B (zh) 沃替西汀氢溴酸盐的新结晶形式
ES2991904T3 (es) Cocristal de ácido fosfórico y un agonista de MC1R
ES2860648T5 (es) Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
ES2562843T3 (es) Forma IV de clorhidrato de ivabradina
ES2982834T3 (es) Sal hidrobromuro cristalina de 5-MeO-DMT
AU2012252380A1 (en) Polymorph of Linagliptin benzoate
ES2659549T3 (es) Sales cristalinas de Raltegravir sódico
ES2755396T3 (es) Formas cristalinas de grapiprant
BR112015028096B1 (pt) Forma cristalina de um hidrato, processo para a preparação da forma cristalina, composição farmacêutica, uso de forma cristalina e combinação farmacêutica
CN103965116B (zh) 半5-氟胞嘧啶盐、其制备方法及应用
ES2553584T3 (es) Polimorfos de Febuxostat
ES2716633T3 (es) Formas cristalinas de fosfato de cabozantinib e hidrocloruro de cabozantinib
ES2214318T3 (es) Cristales de mirtazapina anhidra y procedimiento para su produccion.
CN102964384A (zh) 阿德福韦酯没食子酸共晶及其制备方法和组合物
EP2710008A1 (en) Novel crystalline salts of asenapine with organic di-acids and tri-acids
ES2949414T3 (es) Formas cristalinas de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida
ES2928785T3 (es) Sal de edaravona
ES2547920T3 (es) Un complejo de tomoxiprol amorfo y ciclodextrina con una rápida velocidad de disolución y procedimiento para su preparación
ES2401709T3 (es) Ácido 4-amino-3-(4-clorofenil)butanoico ópticamente activo
ES2327265T3 (es) Una nueva forma cristalina estable de andolast.
ES2875402T3 (es) Tosilato de palbociclib
ES2386029T3 (es) Formas sólidas de un antagonista de receptor de quimiocina y procedimientos de uso del mismo
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
BR112016003169B1 (pt) Polimorfo cristalino de forma 2, composição farmacêutica, uso do polimorfo cristalino de forma 2 e método para a preparação do polimorfo cristalino de forma 2